Repository logo
 

Germline variants in UHRF1 are associated with multilocus imprinting disturbance in humans and mice.

Accepted version
Peer-reviewed

Loading...
Thumbnail Image

Change log

Abstract

The investigation of congenital imprinting disorders (CIDs) provides opportunities to elucidate the molecular mechanisms and role of genomic imprinting in development and human disease. Beckwith-Wiedemann spectrum (BWSp) is a prototypic CID resulting from genetic and epigenetic alterations of imprinted genes at chromosome 11p15.5. In up to a quarter of individuals with BWSp, the epigenetic alterations are not confined to 11p15.5 imprinting control regions but also involve other imprinted gene clusters (multilocus imprinting disturbance; MLID). In a consanguineous family with two children diagnosed with BWSp and MLID, the affected individuals were homozygous for a missense variant in UHRF1, a gene previously implicated in the maintenance of DNA methylation. To investigate whether the UHRF1 c. 2001G>C, p.(Lys667Asn) missense substitution predisposes to abnormal establishment/maintenance of genomic imprinting patterns, a genetically engineered mouse model with a Uhrf1 p.(Lys661Asn) variant was developed. Mice homozygous for the variant born to heterozygous mothers did not display an abnormal phenotype, but homozygotes born to healthy homozygous mothers displayed a range of phenotypes including prenatal lethality. Also, MLID was observed in affected mouse embryos. These findings are consistent with biallelic UHRF1 variants in affected individuals resulting in an autosomal recessively inherited cause of MLID in humans and expand the range of epigenetic disorders associated with UHRF1.

Description

Journal Title

Proc Natl Acad Sci U S A

Conference Name

Journal ISSN

0027-8424
1091-6490

Volume Title

Publisher

Proceedings of the National Academy of Sciences

Rights and licensing

Except where otherwised noted, this item's license is described as Attribution 4.0 International
Sponsorship
Medical Research Council (MC_UU_12012/4)
National Institute for Health and Care Research (IS-BRC-1215-20014)
This research was co-funded by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014) and Rosetrees Trust (to EO, SL and ERM), Marie Curie Initial Training Network Award (INGENIUM) (BLL, ERM), from the European Union, Alan Turing Institute under the Engineering and Physical Sciences Research Council [EP/N510129/1 to LB], King Abdullah University of Science and Technology (KAUST) [OSR-GRG2019-4043 to WF, MC, EM] Medical Research Council [MRC_MC_UU_12012/4 to MC; MRC_MC_UU_12012/5 to the MRC Metabolic Diseases Unit] and EpiGenRare MRC Rare Diseases Node funding MR/Y008170/1 to ERM].